Announcement PDF ® IMAGION BIOSYSTEMS LIMITED (ASX: IBX) 14 July 2020 Imagion Biosystems announces transition of CFO role MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, announces that its Chief Financial Officer, Brian Conn, will be leaving the Company effective 1st August 2020. Brian has served as a part-time CFO since 2017 and is moving on to take a full time CFO position with another of his clients. The company has commenced the process of searching for a replacement, with the intention of appointing an Australian-based CFO, with an increased focus on investor relations responsibilities. Bob Proulx, Executive Chairman said, “On behalf of the Board, I would sincerely like to thank Brian and recognise his commitment and achievements at Imagion Biosystems over the past three years. Brian has been instrumental in our early formative period, however, this change creates an opportunity to add a senior member to the executive management team that is based in Australia – closer to our investors and the capital markets – to support the company through its next phase as we look to advance our business beyond our upcoming initial clinical study.” “I’ve appreciated the opportunity to be part of Imagion’s early development”, said Brian Conn. “I feel Imagion is in a strong position following the recent capital raise and clinical progress. The Company is in capable hands with respect to financial reporting and compliance and I will be available to assist Imagion if needed. I remain a shareholder and supporter of Imagion’s potential to change the way cancer is diagnosed treated and I look forward to the company’s success in the future.” About Imagion Biosystems Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017. -ENDS For further information please visit www.imagionbiosystems.com This Announcement has been approved by the Disclosure Committee of Imagion Biosystems Limited. U.S. Media Contact: Matthew Wygant matthew@biotechwriting.com +1-408-905-7630 Australian Media & Investor Relations: Kyahn Williamson, WE Communications We-AUImagionBiosystems@we-worldwide.com +61 (0) 401018828 Imagion Biosystems Limited ACN 616 305 027 Level 25, 525 Collins Street, Melbourne VIC 3000 www.imagionbiosystem.com